Nonspecific plasma proteins during sublingual immunotherapy

Chemical Immunology and Allergy

Volumn 82, Issue , 2003, Pages 99-108

  Reich, M ^a   Zwacka, G ^b   Markert, Udo ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b Robert Koch Hospital Gehrden   (Germany)

Author keywords

Allergy; Immunoglobulin E; Immunoglobulin G4; Interleukin; Interleukin 2 receptor; sE selectin; Soluble intercellular adhesion molecule 1; Sublingual immunotherapy

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G4; IMMUNOLOGIC AGENT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR; PLASMA PROTEIN; ALLERGEN;

ALLERGIC ASTHMA; ALLERGIC RHINITIS; ALLERGY; ARTICLE; BIRCH; CHILD; CONTROLLED STUDY; DERMATITIS; DERMATOPHAGOIDES PTERONYSSINUS; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; GRASS POLLEN; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIZATION; ADOLESCENT; AGE; BLOOD; DESENSITIZATION; PRESCHOOL CHILD; PROCEDURES; SUBLINGUAL DRUG ADMINISTRATION;

ADMINISTRATION, SUBLINGUAL; ADOLESCENT; AGE FACTORS; ALLERGENS; CHILD; CHILD, PRESCHOOL; DESENSITIZATION, IMMUNOLOGIC; E-SELECTIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; RECEPTORS, INTERLEUKIN-2;

EID: 0345761350     PISSN: 16602242     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000071544     Document Type: Article

References (37)

1. Rothlein R, Mainolfi EA, Czajkowsi M, Marlin SD: A form of circulating ICAM-1 in human serum. J Immunol 1991;147:3488-3493.
2. Minami Y, Kono T, Miyazaki T, Taniguchi T: The IL-2 receptor complex: Its structure, function, and target genes. Annu Rev Immunol 1993;11:245-268.
3. Honda M, Kitamura K, Takeshita T, Sugamura K, Tokunaga T: Identification of a soluble IL-2 receptor beta-chain from human lymphoid cell line cells. J Immunol 1990;145:4131-4135.
4. Binns RM, Licence ST, Harrison AA, Keelan ET, Robinson MK, Haskard DO: In vivo E-selectin upregulation correlates early with infiltration of PMN, later with PBL entry: MAbs block both. Am J Physiol 1996;270:183-193.
5. Oehling A, Sanz ML, Garcia BE: Immunological parameters in the immunotherapy follow-up. Int Arch Allergy Immunol 1992;99:474-477.
6. Reich M, Niess JH, Bär C, Zwacka G, Markert UR: Elevated non-specific plasma proteins in allergic patients. J Investig Allergol Clin Exp, in press.
7. El Sawy IH, Badr El Din OM, El Azzouni OE, Motawae HA: Soluble intercellular adhesion molecule-1 in sera of children with bronchial asthma exacerbation. Int Arch Allergy Immunol 1999;119:126-132.
8. Cengizlier R, Demirpolat E, Tulek N, Cakmak F: Circulating ICAM-1 levels in bronchial asthma and the effect of inhaled corticosteroids. Ann Allergy Asthma Immunol 2000;84:539-541.
9. Hashimoto S, Imai K, Kobayashi T, Amemiya E, Takahashi Y, Tomita Y, Iwata T, Suguro H, Yamaguchi M, Yachi A: Elevated levels of soluble ICAM-1 in sera from patients with bronchial asthma. Allergy 1993;48:370-372.
10. Wuthrich B, Joller-Jemelka H, Kagi MK: Levels of soluble ICAM-1 in atopic dermatitis. A new marker for monitoring the clinical activity? Allergy 1995;50:88-89.
11. Passalacqua G, Senna G, Dama A, Riccio A, Crivellaro M, Canonica GW: The relationship between clinical efficacy of specific immunotherapy and serum intercellular adhesion molecule-1 levels. J Investig Allergol Clin Immunol 1998;8:123-124.
12. Ohashi Y, Nakai Y, Tanaka A, Kakinoki Y, Ohno Y, Masamoto T, Sakamoto H, Kato A, Washio Y, Yamada K, Hayashi M: Clinical role of soluble adhesion molecules during immunotherapy for perennial allergic rhinitis. Arch Otolaryngol Head Neck Surg 1998;124:41-45.
13. Ohashi Y, Nakai Y, Tanaka A, Kakinoki Y, Ohno Y, Masamoto T, Sakamoto H, Kato A, Washio Y, Hayashi M: Serum levels of specific IgE, soluble interleukin-2 receptor, and soluble intercellular adhesion molecule-1 in seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997;79:213-220.
14. Ohashi Y, Nakai Y, Tanaka A, Kakinoki Y, Ohno Y, Masamoto T, Sakamoto H, Kato A, Washio Y, Hayashi M: Soluble intercellular adhesion molecule-1 level in sera is elevated in perennial allergic rhinitis. Laryngoscope 1997;107:932-935.
15. Yamashita N, Kaneko S, Kouro O, Furue M, Yamamoto S, Sakane T: Soluble E-selectin as a marker of disease activity in atopic dermatitis. J Allergy Clin Immunol 1997;99:410-416.
16. Wolkerstorfer A, Laan MP, Savelkoul HF, Neijens HJ, Mulder PG, Oudesluys-Murphy AM, Sukhai RN, Oranje AP: Soluble E-selectin, other markers of inflammation and disease severity in children with atopic dermatitis. Br J Dermatol 1998;138:431-435.
17. Koide M, Furukawa F, Tokura Y, Shirahama S, Takigawa M: Evaluation of soluble cell adhesion molecules in atopic dermatitis. J Dermatol 1997;24:88-93.
18. Hirai S, Kageshita T, Kimura T, Tsujisaki M, Okajima K, Imai K, Ono T: Soluble intercellular adhesion molecule-1 and soluble E-selectin levels in patients with atopic dermatitis. Br J Dermatol 1996;134:657-661.
19. Czech W, Schopf E, Kapp A: Soluble E-selectin in sera of patients with atopic dermatitis and psoriasis - Correlation with disease activity. Br J Dermatol 1996;134:17-21.
20. Morita H, Kitano Y, Kawasaki N: Elevation of serum-soluble E-selectin in atopic dermatitis. J Dermatol Sci 1995;10:145-150.
21. Kowalzick L, Kleinheinz A, Neuber K, Weichenthal M, Kohler I, Ring J: Elevated serum levels of soluble adhesion molecules ICAM-1 and ELAM-1 in patients with severe atopic eczema and influence of UVA1 treatment. Dermatology 1995;190:14-18.
22. Laan MP, Koning H, Baert MR, Oranje AP, Buurman WA, Savelkoul HF, Neijens HJ: Levels of soluble intercellular adhesion molecule-1, soluble E-selectin, tumor necrosis factor-alpha, and soluble tumor necrosis factor receptor p55 and p75 in atopic children. Allergy 1998;53:51-58.
23. Tsai LC, Tang RB, Hung MW, Chen HM, Tsai SJ: Expression of serum IL-2, IL-2R, and CD8 levels during hyposensitization in house-dust-sensitive asthmatics. J Asthma 1990;27:307-313.
24. Shi HZ, Sun JJ, Pan HL, Lu JQ, Zhang JL, Jiang JD: Alterations of T-lymphocyte subsets, soluble IL-2 receptor, and IgE in peripheral blood of children with acute asthma attacks. J Allergy Clin Immunol 1999;103:388-394.
25. Ohashi Y, Nakai Y, Sakamoto H, Ohno Y, Sugiura Y, Okamoto H, Tanaka A, Kakinoki Y, Kishimoto K, Hayashi M: Serum levels of soluble interleukin-2 receptor in patients with perennial allergic rhinitis before and after immunotherapy. Ann Allergy Asthma Immunol 1996;77:203-208.
26. Ohashi Y, Nakai Y, Tanaka A, Kakinoki Y, Washio Y, Kato A, Masamoto T, Sakamoto H, Yamada K: Ten-year follow-up study of allergen-specific immunoglobulin E and immunoglobulin G4, soluble interleukin-2 receptor, interleukin-4, soluble intercellular adhesion molecule-1 and soluble vascular cell adhesion molecule-1 in serum of patients on immunotherapy for perennial allergic rhinitis. Scand J Immunol 1998;47:167-178.
27. Lee YL, Fu CL, Ye YL, Chiang BL: Administration of interleukin-12 prevents mite Der p 1 allergen-IgE antibody production and airway eosinophil infiltration in an animal model of airway inflammation. Scand J Immunol 1999;49:229-236.
28. Gavett SH, O'Hearn DJ, Li X, Huang SK, Finkelman FD, Wills-Karp M: Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice. J Exp Med 1995;182:1527-1536.
29. Fanta C, Bohle B, Hirt W, Siemann U, Horak F, Kraft D, Ebner H, Ebner C: Systemic immunological changes induced by administration of grass pollen allergens via the oral mucosa during sublingual immunotherapy. Int Arch Allergy Immunol 1999;120:218-224.
30. Bousquet J, Scheinmann P, Guinnepain MT, Perrin Fayolle M, Sauvaget J, Tonnel AB, Pauli G, Caillaud D, Dubost R, Leynadier F, Vervloet D, Herman D, Galvain S, Andre C: Sublingualswallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: A double-blind, placebo-controlled study. Allergy 1999;54:249-260.
31. La Rosa M, Ranno C, Andre C, Carat F, Tosca MA, Canonica GW: Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 1999;104:425-432.
32. Clavel R, Bousquet J, Andre C: Clinical efficacy of sublingual-swallow immunotherapy: A double-blind, placebo-controlled trial of a standardized five-grass-pollen extract in rhinitis. Allergy 1998;53:493-498.
33. Mungan D, Misirligil Z, Gurbuz L: Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma - A placebo controlled study. Ann Allergy Asthma Immunol 1999;82:485-490.
34. Ambrosio F, Ricciardi L, Isola S, Savi E, Parmiani S, Puccinelli P, Musarra A: Rush sublingual immunotherapy in Parietaria allergic patients. Allergol Immunopathol (Madr) 1996;24:146-151.
35. Vourdas D, Syrigou E, Potamianou P, Carat F, Batard T, Andre C, Papageorgiou PS: Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy 1998;53:662-672.
36. Guez S, Vatrinet C, Fadel R, Andre C: House-dust-mite sublingual-swallow immunotherapy (SL1T) in perennial rhinitis: A double-blind, placebo-controlled study. Allergy 2000;55:369-375.
37. Djurup R, Malling HJ: High IgG4 antibody level is associated with failure of immunotherapy with inhalant allergens. Clin Allergy 1987;17:459-468.